METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion
METTL1-deficient MSCs alleviate MASLD-associated lipid metabolic disorders via NAMPT secretion. This suggests that genetically modified MSCs targeting METTL1 may represent a promising therapeutic strategy for the treatment of MASLD.
Authors
- Hongen Zhang (ORCID: https://orcid.org/0000-0002-9886-2156)
- Dunyong Zhao
- Yang Zhang (ORCID: https://orcid.org/0000-0002-0883-8233)
- Juntang Lin (ORCID: https://orcid.org/0000-0002-4203-8117)
- Yuyuan WANG
- Chiheng Wang
- Jiang Du
Institutions
- Army Medical University (CN)
- Southwest Hospital (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- Stem Cells Translational Medicine
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1093/stcltm/szag016
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00